Cargando…

A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

BACKGROUND: Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with increased risk of cardiovascular or chronic kidney diseases; in addition, boosted regimens are particularly associated with drug-drug interactions. Since both cardiovascular and renal disease, and poly...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwuji, Collins C., Churchill, Duncan, Bremner, Stephen, Perry, Nicky, To, Ye, Lambert, Debbie, Bruce, Chloe, Waters, Laura, Orkin, Chloe, Geretti, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370264/
https://www.ncbi.nlm.nih.gov/pubmed/32689975
http://dx.doi.org/10.1186/s12879-020-05240-y
_version_ 1783560954393395200
author Iwuji, Collins C.
Churchill, Duncan
Bremner, Stephen
Perry, Nicky
To, Ye
Lambert, Debbie
Bruce, Chloe
Waters, Laura
Orkin, Chloe
Geretti, Anna Maria
author_facet Iwuji, Collins C.
Churchill, Duncan
Bremner, Stephen
Perry, Nicky
To, Ye
Lambert, Debbie
Bruce, Chloe
Waters, Laura
Orkin, Chloe
Geretti, Anna Maria
author_sort Iwuji, Collins C.
collection PubMed
description BACKGROUND: Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with increased risk of cardiovascular or chronic kidney diseases; in addition, boosted regimens are particularly associated with drug-drug interactions. Since both cardiovascular and renal disease, and polypharmacy, are common in ageing people with HIV, there is a need for alternative efficacious regimens. bPI-based regimens are often the treatment of choice for individuals with pre-treatment or treatment-acquired resistance but it is plausible that carefully selected HIV-positive individuals with drug resistance, who are virologically suppressed on their current bPI regimen, could maintain virological efficacy when switched to bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) fixed dose combination (FDC). METHODS/DESIGN: A phase IV, investigator-initiated, multicentre, open label pilot, randomised two-arm study to assess the safety and efficacy of switching from bPI regimen to B/F/TAF single tablet regimen in integrase inhibitor-naïve, virologically suppressed adults with HIV-1 infection harbouring drug resistance mutations. Eligible individuals will either continue on their bPI regimen or switch to B/F/TAF FDC. After 24 weeks, all participants in the bPI arm will be switched to B/F/TAF and followed for a further 24 weeks and all participants will be followed for 48 weeks. The primary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at week 24 using pure virologic response whilst the secondary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48. Other secondary outcome measures include between arm comparisons of drug resistance at virological failure, safety and tolerability and patient-reported outcome measures. DISCUSSION: We aim to provide preliminary evidence of the efficacy of switching to B/F/TAF in patients with virological suppression on a bPI-based regimen who harbour select drug resistance mutations. TRIAL REGISTRATION: ISRCTN 44453201, registered 19 June 2019 and EudraCT 2018–004732-30.
format Online
Article
Text
id pubmed-7370264
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73702642020-07-20 A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial Iwuji, Collins C. Churchill, Duncan Bremner, Stephen Perry, Nicky To, Ye Lambert, Debbie Bruce, Chloe Waters, Laura Orkin, Chloe Geretti, Anna Maria BMC Infect Dis Study Protocol BACKGROUND: Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with increased risk of cardiovascular or chronic kidney diseases; in addition, boosted regimens are particularly associated with drug-drug interactions. Since both cardiovascular and renal disease, and polypharmacy, are common in ageing people with HIV, there is a need for alternative efficacious regimens. bPI-based regimens are often the treatment of choice for individuals with pre-treatment or treatment-acquired resistance but it is plausible that carefully selected HIV-positive individuals with drug resistance, who are virologically suppressed on their current bPI regimen, could maintain virological efficacy when switched to bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) fixed dose combination (FDC). METHODS/DESIGN: A phase IV, investigator-initiated, multicentre, open label pilot, randomised two-arm study to assess the safety and efficacy of switching from bPI regimen to B/F/TAF single tablet regimen in integrase inhibitor-naïve, virologically suppressed adults with HIV-1 infection harbouring drug resistance mutations. Eligible individuals will either continue on their bPI regimen or switch to B/F/TAF FDC. After 24 weeks, all participants in the bPI arm will be switched to B/F/TAF and followed for a further 24 weeks and all participants will be followed for 48 weeks. The primary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at week 24 using pure virologic response whilst the secondary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48. Other secondary outcome measures include between arm comparisons of drug resistance at virological failure, safety and tolerability and patient-reported outcome measures. DISCUSSION: We aim to provide preliminary evidence of the efficacy of switching to B/F/TAF in patients with virological suppression on a bPI-based regimen who harbour select drug resistance mutations. TRIAL REGISTRATION: ISRCTN 44453201, registered 19 June 2019 and EudraCT 2018–004732-30. BioMed Central 2020-07-20 /pmc/articles/PMC7370264/ /pubmed/32689975 http://dx.doi.org/10.1186/s12879-020-05240-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Iwuji, Collins C.
Churchill, Duncan
Bremner, Stephen
Perry, Nicky
To, Ye
Lambert, Debbie
Bruce, Chloe
Waters, Laura
Orkin, Chloe
Geretti, Anna Maria
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
title A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
title_full A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
title_fullStr A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
title_full_unstemmed A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
title_short A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
title_sort phase iv randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in integrase inhibitor-naïve, virologically suppressed hiv-1 infected adults harbouring drug resistance mutations (pibik study): study protocol for a randomised trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370264/
https://www.ncbi.nlm.nih.gov/pubmed/32689975
http://dx.doi.org/10.1186/s12879-020-05240-y
work_keys_str_mv AT iwujicollinsc aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT churchillduncan aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT bremnerstephen aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT perrynicky aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT toye aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT lambertdebbie aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT brucechloe aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT waterslaura aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT orkinchloe aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT gerettiannamaria aphaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspi
AT iwujicollinsc phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib
AT churchillduncan phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib
AT bremnerstephen phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib
AT perrynicky phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib
AT toye phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib
AT lambertdebbie phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib
AT brucechloe phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib
AT waterslaura phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib
AT orkinchloe phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib
AT gerettiannamaria phaseivrandomisedopenlabelpilotstudytoevaluateswitchingfromproteaseinhibitorbasedregimentobictegraviremtricitabinetenofoviralafenamidesingletabletregimeninintegraseinhibitornaivevirologicallysuppressedhiv1infectedadultsharbouringdrugresistancemutationspib